期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ijms23010100
关键词
melatonin; diabetes mellitus; diabetic neuropathy; diabetic retinopathy
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [307968/2020-0]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP) (grant: PRONEX/FUNCAP/CNPq)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2019/24327-5]
Studies suggest that melatonin (MEL) has therapeutic potential as an adjunct treatment for neural complications of diabetes mellitus (DM). However, variations in dosage, treatment duration, and treatment timing hinder objective analysis of the progress and establishment of parameters for the validation of MEL in the treatment of neural complications of DM.
Diabetes mellitus (DM) leads to complications, the majority of which are nephropathy, retinopathy, and neuropathy. Redox imbalance and inflammation are important components of the pathophysiology of these complications. Many studies have been conducted to find a specific treatment for these neural complications, and some of them have investigated the therapeutic potential of melatonin (MEL), an anti-inflammatory agent and powerful antioxidant. In the present article, we review studies published over the past 21 years on the therapeutic efficacy of MEL in the treatment of DM-induced neural complications. Reports suggest that there is a real prospect of using MEL as an adjuvant treatment for hypoglycemic agents. However, analysis shows that there is a wide range of approaches regarding the doses used, duration of treatment, and treatment times in relation to the temporal course of DM. This wide range hinders an objective analysis of advances and prospective vision of the paths to be followed for the unequivocal establishment of parameters to be used in an eventual therapeutic validation of MEL in neural complications of DM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据